Ruxolitinib (Jakafi)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Kinase inhibitor of Janus Associated Kinases (JAKs) JAK1 and JAK2. Modulates gene expression by interfering with the JAK signaling pathway, which involves recruitment, activation, and localization of STATs (signal transducers and activators of transcription) to cytokine receptors and the nucleus.[1][2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1][3]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code name: INCB018424
  • Generic name: ruxolitinib phosphate
  • Brand names: Jakafi, Jakavi

References

  1. 1.0 1.1 1.2 Ruxolitinib (Jakafi) package insert
  2. Ruxolitinib (Jakafi) package insert (locally hosted backup)
  3. Jakafi manufacturer's website
  4. Ruxolitinib (Jakafi) patient drug information (Chemocare)
  5. Ruxolitinib (Jakafi) patient drug information (UpToDate)